Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies[ Breast Cancer Res Treat (2014), 148, 553-561, DOI 10.1007/s10549-014-3144-y];Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

Breast Cancer Research and Treatment

Volumn 148, Issue 3, 2014, Pages 553-561

  Twelves, Chris ^a   Cortes, Javier ^b   Vahdat, Linda ^c   Olivo, Martin ^d   He, Yi ^d   Kaufman, Peter A ^e   Awada, Ahmad ^f  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d EISAI INC   (United States)

^e NORRIS COTTON CANCER CENTER   (United States)

^f JULES BORDET INSTITUTE   (Belgium)

Author keywords

Eribulin mesylate; Halaven; Metastatic breast cancer; Pooled analysis

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; ANTHRACYCLINE; BRIDGED COMPOUND; DEOXYCYTIDINE; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; FURAN DERIVATIVE; KETONE; TAXANE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; YOUNG ADULT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CAPECITABINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FURANS; HUMANS; KETONES; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84912035048     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3245-7     Document Type: Erratum

References (21)

1. National Cancer Institute (2013) SEER Cancer Statistics Review, 1975–2010. National Cancer Institute, Bethesda, based on November 2012 SEER data submission, posted to the SEER web site. http://seer.cancer.gov/csr/1975_2010. Accessed 18 Jul 2013
2. Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB (2011) Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol 12:1053–1061. doi:10.1016/S1470-2045(11)70045-6
3. Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N (2013) Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 12:CD008792. doi:10.1002/14651858.CD008792.pub2
4. Andreopoulou E, Sparano JA (2013) Chemotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer: an overview. Curr Breast Cancer Rep 5:42–50. doi:10.1007/s12609-012-0097-1
5. Al-Batran SE, Guntner M, Pauligk C, Scholz M, Chen R, Beiss B, Stopatschinskaja S, Lerbs W, Harbeck N, Jager E (2010) Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer 103:1518–1523. doi:10.1038/sj.bjc.66059616605961
6. Toulmonde M, Madranges N, Brouste V, Donamaria C, MacGrogan G, Durand M, Bonnefoi H, Mauriac L, Debled M (2012) Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity. Breast Cancer Res Treat 134:325–332. doi:10.1007/s10549-012-2060-2
7. National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology breast cancer, version 3. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 18 Jul 2013
8. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E (2012) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii11–vii19. doi:10.1093/annonc/mds232
9. Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923. doi:10.1016/S0140-6736(11)60070-6
10. Twelves C, Akerele C, Wanders J, Cortes JA (2010) Eribulin mesylate (E7389) vs treatment of physician’s choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Ann Oncol 21(Suppl 8):Abstract 2750
11. Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Wanders J, Olivo MS, He Y, Dutcus CE (2012) A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res 72(24 Suppl):Abstract S6–6. doi:10.1158/0008-5472.SABCS12-S6-6
12. Chang IM, Gelman R, Pagano M (1982) Corrected group prognostic curves and summary statistics. J Chronic Dis 35:669–674
13. Makuch RW (1982) Adjusted survival curve estimation using covariates. J Chronic Dis 35:437–443
14. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN (1999) Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 85:104–111
15. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H (1996) A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165–171
16. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009) Triple-negative breast cancer—current status and future directions. Ann Oncol 20:1913–1927. doi:10.1093/annonc/mdp492
17. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434. doi:10.1158/1078-0432.CCR-06-3045
18. Anders CK, Carey LA (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9:S73–S81. doi:10.3816/CBC.2009.s.008
19. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106. doi:10.1093/jnci/dju055
20. Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states. Br J Cancer 110:1497–1505. doi:10.1038/bjc.2014.80
21. Vahdat L, Schwartzberg L, Wilks S, Rege J, Liao J, Cox D, O’Shaughnessy J (2012) Eribulin mesylate+trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a phase 2, multicenter, single-arm study. Cancer Res 72(24 Suppl):Abstract P5-20-04